Cancer is recognized as a major cause of mortality world over; accounting for 7.4 million (or 13%) of all deaths in 2004. The WHO estimates the incidence of cancer to continue rising to reach an estimated 9.2 million deaths in 2015. The rising prevalence of the disease forms one of the major factors driving the growth of the oncology biomarkers market.
Biomarker are chemical, physical, or biological parameters that can be used to indicate disease states. Oncology biomarkers facilitate high-speed, non-invasive cancer diagnosis; and are believed to enhance early cancer detection and screening. The demand for oncology biomarkers is also increasing because of their ability to trace the exact type of cancer and to target patient-specific molecular structure.
The oncology biomarkers market offers high-growth opportunities with the numerous initiatives to encourage biomarker-based cancer treatment. Government agencies such as Food and Drug Administration (FDA) and the National Cancer Institute (NCI) ) are have taken an active interest in the field, especially with the declining success to failure rate of oncology drugs
Market Estimates and Forecasts
The report categorizes the Global oncology biomarkers market as follows:
Oncology biomarkers discovery market
Oncology biomarkers diagnostics market
Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments and micro-markets. In addition, the report also provides more than 15 company profiles for each of its sub-segments.
What makes our reports unique?
We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
Comprehensive market analysis for the following sectors:
Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.
Key questions answered
Which are the high-growth segments/cash cows and how is the market segmented in terms of oral drugs, injectables?
What are market estimates and forecasts; which markets are doing well and which are not?
Where are the gaps and opportunities; what is driving the market?
Which are the key playing fields? Which are the winning edge imperatives?
How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?
Powerful Research and analysis
The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world.
CANCER BIOMARKER MARKET
EXECUTIVE SUMMARY
. MARKET OVERVIEW
. MARKET DYNAMICS
. CANCER BIOMARKERS DIAGNOSTICS MARKET
. CANCER BIOMARKERS DISCOVERY MARKET
. GEOGRAPHICAL ANALYSIS
. COMPETITIVE LANDSCAPE
1 INTRODUCTION
1.1 Key take-aways
1.2 Report description
1.3 Markets covered
1.4 Research methodology
1.5 Stakeholders
2 SUMMARY
3 MARKET OVERVIEW
3.1 Introduction
3.2 Defining the market
3.3 Classification of cancer biomarkers
3.4 Factors influencing market growth
3.5 Market share analysis
3.5.1 By market segments
3.5.2 By market players
3.6 Patent analysis
4 MARKET DYNAMICS
4.1 Introduction
4.2 Drivers
4.2.1 Enhanced accuracy & speed of diagnosis
4.2.2 Streamlined drug delivery process
4.2.3 Increased survival rates
4.2.4 Non-invasive diagnosis
4.2.5 U.S. Government initiatives
4.2.6 Helps in fda approvals for cancer drugs
4.2.7 Demographic & other factors
4.3 Restraints
4.3.1 High cost & complexity of biomarker validation
4.3.2 Reimbursement issues
4.3.3 Other validation issues
4.3.4 Need for immediate processing
5 CANCER BIOMARKERS DIAGNOSTICS MARKET
5.1 Introduction
5.2 Immunoassays
5.3 Immunohistochemical (IHC) tests
5.4 Molecular (DNA and genomic) diagnostic assays
5.5 Genetic and genomic markers
5.6 Proteomics
5.7 Flow cytometry
5.8 Stem cell markers
5.9 Monoclonal antibodies
5.10 Pharmacogenomics
5.11 DNA microarrays
5.12 IVD multivariate index assays (IVDMIA)
6 CANCER BIOMARKERS DISCOVERY MARKET
6.1 Metabolomics
6.2 Genetic methods
6.2.1 DNA arrays
6.2.2 Southern blot
6.2.3 Polymerase chain reaction (PCR)
6.2.4 Reverse transcriptase polymerase chain reaction (RT-PCR)
6.2.5 Fluorescent in situ hybridization (FISH)
6.3 Protein methods
6.3.1 Immunohistochemistry (IHC)
6.3.2 Mass spectrometry (MS)
6.4 Imaging
6.4.1 Positron emission tomography (PET)
6.4.2 Computed tomography (CT)
6.4.3 Magnetic resonance imaging (MRI)
6.4.4 Magnetic resonance spectroscopy (MRS)
6.4.5 Single-photon emission computed tomography (SPECT)
6.4.6 X-ray
6.4.7 Biophotonics
6.4.8 Ultrasound
7 GEOGRAPHICAL ANALYSIS
7.1 North America
7.2 Europe
7.3 Asia
7.4 ROW
8 COMPETITIVE LANDSCAPE
9 COMPANY PROFILES
9.1 ABBOTT LABORATORIES
9.2 AFFYMETRIX, INC
9.3 AGENDIA BV
9.4 AMBRILIA BIOPHARMA
9.5 ASTELLAS PHARMA US INC
9.6 AUREON LABORATORIES, INC
9.7 BECKMAN COULTER, INC
9.8 BECTON, DICKINSON AND COMPANY
9.9 BIOCUREX INC
9.10 BIOMERIEUX S.A.
9.11 BIOMODA, INC
9.12 CLARIENT, INC
9.13 CORRELOGIC SYSTEMS, INC
9.14 DIADEXUS, INC
9.15 DIAGNOCURE INC
9.16 EPIGENOMICS AG
9.17 EUSA PHARMA (USA) INC
9.18 EXACT SCIENCES CORP
9.19 FUJIREBIO DIAGNOSTICS, INC
9.20 GEN-PROBE, INC
9.21 GENOMIC HEALTH INC
9.22 GERON CORP
9.23 HOLOGIC INC
9.24 IMMUNOMEDICS, INC
9.25 INVERNESS MEDICAL INNOVATIONS, INC
9.26 LABORATORY CORP. OF AMERICA HOLDINGS
9.27 MORPHOTEK, INC
9.28 MYRIAD GENETICS, INC
9.29 NORTHWEST BIOTHERAPEUTICS INC
9.30 OCIMUM BIOSOLUTIONS LTD
9.31 ONCOTHYREON, INC
9.32 POLYMEDCO INC
9.33 PONIARD PHARMACEUTICALS INC
9.34 QIAGEN N.V.
9.35 RADIENT PHARMACEUTICALS CORP
9.36 SIEMENS HEALTHCARE
9.37 VERIDEX LLC
APPENDIX
. U.S. Patents
. Europe Patents
. Japan Patents
LIST OF TABLES
Summary Table Global Cancer Biomarker Market, By Segments 2007-2014 ($Million)
1 List of FDA approved biomarkers
2 FDA initiatives for cancer biomarkers
3 Global cancer biomarker diagnostic market, by technologies 2007-2014 ($Million)
4 Global cancer biomarker diagnostic market, by geography 2007-2014 ($Million)
5 Global immunoassays market, by geography 2007-2014 ($Million)
6 Global immunohistochemical tests market, by geography 2007-2014 ($Million)
7 Global molecular (DNA and genomic) diagnostic assays market, By Geography 2007-2014 ($Million)
8 Global genomics and genetic markers market, by geography 2007-2014 ($Million)
9 Global proteomics market, by geography 2007-2014 ($Million)
10 Global flow cytometry market, by geography 2007-2014 ($Million)
11 Global stem cell markers market, by geography 2007-2014 ($Million)
12 Global monoclonal antibodies market, by geography 2007-2014 ($Million)
13 Global pharmacogenomics market, by geography 2007-2014 ($Million)
14 Global DNA microarrays market, by geography 2007-2014 ($Million)
15 Global in vitro diagnostic multivariate index assays market, by geography 2007-2014 ($Million)
16 Global cancer biomarker discovery market, by segments 2007-2014 ($Million)
17 Global cancer biomarker discovery market, by geography 2007-2014 ($Million)
18 Global metabolomics market, by geography 2007-2014 ($Million)
19 Global genetic methods market, by methods 2007-2014 ($Million)
20 Global genetic methods market, by geography 2007-2014 ($Million)
21 Global DNA arrays market, by geography 2007-2014 ($Million)
22 Global southern blot market, by geography 2007-2014 ($Million)
23 Global polymerase chain reaction market, by geography 2007-2014 ($Million)
24 Global reverse transcriptase polymerase chain reaction market, by geography 2007-2014 ($Million)
25 Global fluorescent in situ hybridization market, by geography 2007-2014 ($Million)
26 Global protein methods market, by segments 2007-2014 ($Million)
27 Global protein methods market, by geography 2007-2014 ($Million)
28 Global immunohistochemistry market, by geography 2007-2014 ($Million)
29 Global Mass spectrometry market, by geography 2007-2014 ($Million)
30 Global imaging market, by segments 2007-2014 ($Million)
31 Global imaging market, by geography 2007-2014 ($Million)
32 Global positron emission tomography market, by geography 2007-2014 ($Million)
33 Global computed tomography market, by geography 2007-2014 ($Million)
34 Global magnetic resonance imaging market, by geography 2007-2014 ($Million)
35 Global magnetic resonance spectroscopy market, by geography 2007-2014 ($Million)
36 Global single photon emission computed tomography market, by geography 2007-2014 ($Million)
37 Global x-ray market, by geography 2007-2014 ($Million)
38 Global biophotonics market, by geography 2007-2014 ($Million)
39 Global ultrasound market, by geography 2007-2014 ($Million)
40 Global cancer biomarkers market, by geography 2007-2014 ($Million)
41 North American cancer biomarkers market, by segments 2007 - 2014 ($Million)
42 European cancer biomarkers market, by segments 2007-2014 ($Million)
43 Asian cancer biomarkers market, by segments 2007-2014 ($Million)
44 Row cancer biomarkers market, by segments 2007-2014 ($Million)
45 Mergers and acquisitions (2008 - January 2010)
46 New product launches (2008 - March 2010)
47 Agreements and collaborations (2008 - January 2010)
LIST OF FIGURES
1 Cancer biomarker market segmentation
2 Classification of cancer biomarkers
3 Comparative analysis of market drivers
4 Comparative analysis of market restraints
5 Cancer biomarker diagnostics market dynamics
6 Market shares of major players in cancer biomarkers molecular diagnostics
7 Patent analysis by geography (2005 - 2009)
8 Patent analysis by competitors (2004 - March 2010)
9 Drug development process flow
9 Developments in global cancer biomarkers market (2008 - March 2010)
10 Key players in strategic development
Other selected research from the 'Oncology' category:
Triple Analysis: Colorectal Cancer, Angiogenesis and Antibodies
Stakeholder Opinions: Hepatocellular Carcinoma - Growing Market Seeks New Players
Other selected research from the 'Biologicals' category:
Biosimilars (2009 - 2014)
Competitor Analysis: Anti-Infective Antibodies
Product description
The present Competitive Intelligence Report about Anti-Infective Antibodies provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies and... Learn More